Published: September 03, 2010
Curis to Present at the Rodman & Renshaw 12th Annual Healthcare Conference
CAMBRIDGE, Mass. - (BUSINESS WIRE) - Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to
develop next generation targeted small molecule drug candidates for
cancer treatment, today announced that the company will be presenting at
the Rodman & Renshaw 12th Annual Healthcare Conference at
10:50 a.m. EDT on September 13, 2010, in New York City.
Dan Passeri, Curis' President and Chief Executive Officer, will provide
an overview of the status of GDC-0449, an orally-administered small
molecule Hedgehog Pathway Inhibitor that is being developed by Curis'
collaborator Genentech. Mr. Passeri will also discuss CUDC-101, Debio
0932 and Curis' other targeted cancer programs, in addition to other
corporate activities.
There will be a corresponding webcast of the presentation, which can be
accessed by visiting:
http://www.wsw.com/webcast/rrshq18/cris
The presentation will be archived shortly after the live event and
available for 30 days following the conference. In addition, it will be
available for 30 days on the Investor Relations section of the Curis
website at www.curis.com.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its
innovative signaling pathway drug technologies to seek to create new
targeted small molecule drug candidates for cancer. Curis is building
upon its previous experiences in targeting signaling pathways, including
in the Hedgehog pathway, in its effort to develop proprietary targeted
cancer programs. For more information, visit Curis' website at www.curis.com.

Curis, Inc.
Michael P. Gray, 617-503-6632
CFO & COO
mgray@curis.com
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News